

# BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.)

Tel. 0731-2426700; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2426700

**Date: 13<sup>th</sup> February, 2026**

To, The Secretary ( <b>DCS/Compliance</b> ), Corporate Relationship Department, <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary ( <b>Listing/Compliance</b> ), Corporate Relationship Department, <b>National Stock Exchange of India Limited</b> , Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051
--	--

**Subject: Outcome of Board Meeting held on Friday 13<sup>th</sup> February, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Reference: Biofil Chemicals & Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)**

Dear Sir/Madam,

With reference to the above captioned subject and in pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors of the Company in their meeting (Serial No. 07/2025-26) held on today i.e., Friday, 13<sup>th</sup> Day of February, 2026, has inter alia, considered and approved the following businesses:

1. Un-Audited Financial Results of the Company for the quarter and nine month ended on 31<sup>st</sup> December, 2025 along with the limited Review Report thereon. **(Copy of financial results for the quarter as well as nine month ended 31<sup>st</sup> December, 2025 enclosed herewith).**
2. Other routine businesses with the permission of Chair.

Furthermore, copy of Un-Audited Financial Results of the Company shall also be submitted in XBRL mode in integrated filing financials within prescribed time limit from the conclusion of Board Meeting.

The aforesaid Un-Audited Financial Results of the Company shall also be uploaded on the Company's website i.e. [www.biofilgroup.net](http://www.biofilgroup.net) and on the website of the Stock Exchanges i.e. at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com). Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers within prescribed time limit.

The Meeting of the Board of Directors commenced at 03:30 P.M. and concluded at 04:20 P.M.

The above information will also be available on the website of the Company at [www.biofilgroup.net](http://www.biofilgroup.net).

You are requested to please take on record the same.

Thanking you.

Yours Faithfully,

**FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED**

**APOORV JAIN  
COMPANY SECRETARY & COMPLIANCE OFFICER  
M. NO. A71739**

**Independent Auditor's Review Report on the Quarterly and Nine Months ended 31<sup>st</sup> December, 2025 Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To,  
**The Board of Directors**  
**Biofil Chemicals and Pharmaceuticals Limited**  
**Indore (M.P.)**

We have reviewed the accompanying statement of unaudited Standalone Financial results ("the statement") of **Biofil Chemicals and Pharmaceuticals Limited** ("the company") for the quarter ended 31<sup>st</sup> December, 2025 and year to date from 01<sup>st</sup> April, 2025 to 31<sup>st</sup> December, 2025 attached herewith. The Statement has been prepared by the Company's Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 (as amended), in compliance with Regulation 33 issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than

an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would be aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in all material respect in accordance with the applicable recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) prescribed under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the review and significant findings, including any significant deficiencies in internal control that we identify during our review.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For **MAHESHWARI & GUPTA**

**Chartered Accountants**

**FRN: 006179C**



**CA. SUNIL MAHESHWARI**

**Partner**

**M. No. 403346**

Place: Indore

Date: 13/02/2026

UDIN: 26403346RRQRYO6384



<b>XVII</b>	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	7.92	8.36	16.46	257.37	35.81	57.87
<b>XVIII</b>	<b>Paid-Up equity share capital (face value of Rs 10/- each)</b>	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
<b>XIX</b>	<b>Reserves (Excluding Revaluation Reserve)</b>						(125.42)
<b>XX</b>	<b>Earnings per equity shares (for continuing operation):</b>						
	(1) Basic (Rs)	0.05	0.05	0.10	1.58	0.22	0.34
	(2) Diluted (Rs)	0.05	0.05	0.10	1.58	0.22	0.34
<b>XXI</b>	<b>Earnings Per Equity Share (for discontinued operation)</b>						
	(1) Basic (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
<b>XXII</b>	<b>Earnings Per Equity Share (for continuing &amp; discontinued operation)</b>						
	(1) Basic (Rs)	0.05	0.05	0.10	1.58	0.22	0.34
	(2) Diluted (Rs)	0.05	0.05	0.10	1.58	0.22	0.34

- 1 The above unaudited financial results for the Quarter and nine month ended December 31, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on February 13, 2026. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments  
a. Pharma Division  
b. Chemicals Division.
- 4 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- 5 The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors. Further Publication containing a Quick Response Code and the details of the webpage where complete financial results of the company are available will be published in english and hindi newspapers within prescribed time limit.
- 6 Due to the revision in Schedule M (Drugs & Cosmetics Rules), the factory is presently undergoing renovation and upgradation work, therefore manufacturing operations were partially disrupted during the quarter, resulting in a decline in turnover as compared to the previous quarter.

Date: 13th February, 2026

Place : Indore

**FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED**

**KETAN SHAH**  
**CHAIRMAN & MANAGING DIRECTOR**  
(DIN: 08818212)



**Biofil Chemicals and Pharmaceuticals Limited**  
Registered Office: B/12-B, Industrial Estate, Pologround, Indore (M.P.) India, 452015  
CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No.0731-2426700  
Website: www.biofilgroup.net

Segment wise Revenue, Results and Capital Employed for quarter ended and nine month ended 31st December 2025

( Amount in Lakhs)

S.No.	Particulars	QUARTER ENDED			NINE MONTH ENDED		Year Ended
		3 months ended on 31/12/2025	Previous 3 months ended on 30/09/2025	Corresponding 3 months ended in previous year on 31/12/2024	Year to date figures for Current period ended 31/12/2025	Year to date figures for Previous period ended 31/12/2024	Previous Year ended on 31/03/2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Segment Revenue</b>						
	Pharma Unit	85.63	1,214.47	1,204.77	1,784.85	2,126.60	2,666.04
	Chemicals Division	0.00	139.61	214.75	298.11	378.52	674.18
	<b>Gross Turnover</b>	<b>85.63</b>	<b>1,354.08</b>	<b>1,419.52</b>	<b>2,082.96</b>	<b>2,505.12</b>	<b>3,340.22</b>
2	<b>Segment Results</b>						
	Pharma Unit	(10.45)	7.22	(2.34)	266.52	(7.40)	(14.38)
	Chemicals Division	16.73	0.46	25.41	24.54	58.30	87.19
	<b>Total Segment Profit Before Tax</b>	<b>6.28</b>	<b>7.68</b>	<b>23.07</b>	<b>291.06</b>	<b>50.90</b>	<b>72.81</b>
	Interest Income	4.39	3.49	0.06	7.94	0.11	4.42
	Interest Expenses	0.01	0.00	0.97	0.93	2.78	3.62
	Other Unallocable Income net of Expenditure						
	<b>Profit Before Tax</b>	<b>10.67</b>	<b>11.17</b>	<b>22.16</b>	<b>298.07</b>	<b>48.23</b>	<b>73.61</b>
3	<b>Capital Employed</b>						
	<b>Segment Assets (A)</b>						
	Pharma Division	3,860.79	3,842.96	3,040.03	3,860.79	3,040.03	3,472.49
	Chemicals Division	1,692.66	1,693.40	1,478.95	1,692.66	1,478.95	1,623.55
	<b>Total (A)</b>	<b>5,553.45</b>	<b>5,536.36</b>	<b>4,518.98</b>	<b>5,553.45</b>	<b>4,518.98</b>	<b>5,096.04</b>
	<b>Segment Liabilities (B)</b>						
	Pharma Division	3,162.57	3,123.52	2,483.46	3,162.57	2,483.46	2,919.95
	Chemicals Division	255.35	264.38	179.41	255.35	179.41	297.93
	<b>Total (B)</b>	<b>3,417.92</b>	<b>3,387.90</b>	<b>2,662.88</b>	<b>3,417.92</b>	<b>2,662.88</b>	<b>3,217.88</b>
	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>						
	Pharma Division	698.22	719.45	556.57	698.22	556.57	552.54
	Chemicals Division	1,437.31	1,429.02	1,299.54	1,437.31	1,299.54	1,325.62
	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>	<b>2,135.53</b>	<b>2,148.46</b>	<b>1,856.10</b>	<b>2,135.53</b>	<b>1,856.10</b>	<b>1,878.16</b>

Date: 13th February, 2026  
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

**KETAN SHAH**  
**CHAIRMAN & MANAGING DIRECTOR**  
( DIN: 08818212)